Comparative Pharmacology
Head-to-head clinical analysis: METOZOLV ODT versus ZUPLENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METOZOLV ODT versus ZUPLENZ.
METOZOLV ODT vs ZUPLENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective 5-HT3 receptor antagonist; blocks serotonin action at vagal nerve terminals and in the chemoreceptor trigger zone, inhibiting emetic reflex.
Competitive serotonin 5-HT3 receptor antagonist; acts centrally on the chemoreceptor trigger zone and peripherally on GI vagal nerve terminals to inhibit emesis.
2.5 mg to 5 mg orally once daily, as disintegrating tablet; may increase to 10 mg if needed
8 mg administered intraorally as a single dose 1 hour before chemotherapy; may repeat once if vomiting occurs within 30 minutes after initial dose.
None Documented
None Documented
~1.5–2 hours in normal renal function; prolonged to 10–20 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life 3.5 hours; in hepatic impairment increases to 7-9 hours
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites and unchanged drug.
Renal 70% unchanged, fecal 20% (including biliary metabolites), 10% metabolized
Category C
Category C
Antiemetic
Antiemetic